Brokerages expect that HCA Healthcare Inc (NYSE:HCA) will post $11.27 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Eleven analysts have provided estimates for HCA Healthcare’s earnings. The highest sales estimate is $11.42 billion and the lowest is $11.09 billion. HCA Healthcare posted sales of $10.70 billion in the same quarter last year, which suggests a positive year over year growth rate of 5.3%. The business is scheduled to issue its next quarterly earnings results on Tuesday, October 30th.
According to Zacks, analysts expect that HCA Healthcare will report full year sales of $46.16 billion for the current year, with estimates ranging from $45.68 billion to $46.46 billion. For the next financial year, analysts forecast that the firm will report sales of $48.28 billion per share, with estimates ranging from $47.68 billion to $49.13 billion. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for HCA Healthcare.
HCA Healthcare (NYSE:HCA) last announced its earnings results on Wednesday, July 25th. The company reported $2.29 EPS for the quarter, topping the Zacks’ consensus estimate of $2.16 by $0.13. The business had revenue of $11.53 billion during the quarter, compared to the consensus estimate of $11.32 billion. HCA Healthcare had a net margin of 6.21% and a negative return on equity of 61.68%. The firm’s revenue was up 7.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.73 earnings per share.
HCA has been the topic of several recent analyst reports. Morgan Stanley upped their price objective on shares of HCA Healthcare from $105.00 to $115.00 and gave the company an “underweight” rating in a report on Thursday, August 16th. SunTrust Banks restated a “buy” rating and set a $125.00 price objective on shares of HCA Healthcare in a report on Friday, July 20th. Leerink Swann upped their price objective on shares of HCA Healthcare from $140.00 to $150.00 and gave the company an “outperform” rating in a report on Tuesday, September 4th. Credit Suisse Group upped their price objective on shares of HCA Healthcare from $122.00 to $143.00 and gave the company an “outperform” rating in a report on Friday, July 27th. Finally, Piper Jaffray Companies restated a “hold” rating and set a $124.00 price objective on shares of HCA Healthcare in a report on Thursday, July 26th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eighteen have issued a buy rating to the company’s stock. HCA Healthcare has a consensus rating of “Buy” and an average price target of $126.33.
In related news, insider Jonathan B. Perlin sold 12,500 shares of the company’s stock in a transaction that occurred on Thursday, June 21st. The stock was sold at an average price of $108.00, for a total value of $1,350,000.00. Following the sale, the insider now owns 107,894 shares in the company, valued at $11,652,552. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Charles J. Hall sold 34,125 shares of the company’s stock in a transaction that occurred on Friday, August 3rd. The shares were sold at an average price of $129.93, for a total value of $4,433,861.25. Following the completion of the sale, the insider now owns 98,124 shares in the company, valued at approximately $12,749,251.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 182,757 shares of company stock worth $22,468,053. 2.80% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Motley Fool Asset Management LLC boosted its position in HCA Healthcare by 12.5% in the 2nd quarter. Motley Fool Asset Management LLC now owns 3,720 shares of the company’s stock worth $382,000 after purchasing an additional 412 shares in the last quarter. Banque Pictet & Cie SA boosted its position in HCA Healthcare by 0.5% in the 2nd quarter. Banque Pictet & Cie SA now owns 91,929 shares of the company’s stock worth $9,432,000 after purchasing an additional 480 shares in the last quarter. Gideon Capital Advisors Inc. boosted its position in HCA Healthcare by 14.7% in the 2nd quarter. Gideon Capital Advisors Inc. now owns 4,441 shares of the company’s stock worth $456,000 after purchasing an additional 569 shares in the last quarter. Intrust Bank NA boosted its position in HCA Healthcare by 0.8% in the 2nd quarter. Intrust Bank NA now owns 74,417 shares of the company’s stock worth $7,635,000 after purchasing an additional 620 shares in the last quarter. Finally, Huntington National Bank boosted its position in HCA Healthcare by 11.2% in the 2nd quarter. Huntington National Bank now owns 6,442 shares of the company’s stock worth $661,000 after purchasing an additional 648 shares in the last quarter. Hedge funds and other institutional investors own 70.40% of the company’s stock.
HCA opened at $133.84 on Friday. HCA Healthcare has a 52-week low of $71.18 and a 52-week high of $138.18. The company has a debt-to-equity ratio of -7.64, a quick ratio of 1.15 and a current ratio of 1.36. The stock has a market cap of $45.60 billion, a PE ratio of 20.14, a P/E/G ratio of 1.19 and a beta of 0.54.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 28th. Investors of record on Tuesday, September 4th will be given a $0.35 dividend. The ex-dividend date is Friday, August 31st. This represents a $1.40 dividend on an annualized basis and a yield of 1.05%. HCA Healthcare’s dividend payout ratio is currently 21.24%.
About HCA Healthcare
HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.